Shareholders Equity (Details Textual) $ / shares in Units, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Jan. 08, 2019
USD ($)
shares
|
Dec. 11, 2018
USD ($)
shares
|
Dec. 18, 2018
USD ($)
$ / shares
shares
|
Nov. 28, 2018
USD ($)
$ / shares
shares
|
Oct. 28, 2018
shares
|
Dec. 31, 2019
USD ($)
Employees
consultants
$ / shares
shares
|
Dec. 31, 2018
USD ($)
Employees
consultants
$ / shares
shares
|
Oct. 28, 2019
$ / shares
shares
|
Nov. 30, 2017
shares
|
May 31, 2017
$ / shares
shares
|
|
| Shareholders Equity (Textual) | ||||||||||
| Common stock, par value | $ / shares | $ 0.0001 | |||||||||
| Preferred stock, par value | $ / shares | $ 0.0001 | |||||||||
| Fair value granted | $ | $ 1,406 | $ 1,451 | ||||||||
| Weighted average exercise price | $ / shares | $ 0.01 | |||||||||
| Share based compensation expenses | $ | $ 732 | 405 | ||||||||
| Unrecognized compensation expense | $ | 2,308 | 3,026 | ||||||||
| Recongnized expense income | $ | $ 241 | $ 584 | ||||||||
| Issuance of warrrants | 236,552 | |||||||||
| Warrants, description | a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product,b. 118,277 upon achievement of the earlier of the following milestone by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company’s licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement ) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product. | |||||||||
| Public warrants, description | ● in whole and not in part;● at a price of $0.01 per warrant;● at any time during the exercise period;● upon a minimum of 30 days’ prior written notice of redemption;● if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and● if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. | |||||||||
| Preferred Stock | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Preferred stock, shares authorized | 1,000,000 | |||||||||
| New Incentive Plan [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Grant options | $ / shares | $ 1,000 | |||||||||
| Equity incentive plan, description | The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein. | |||||||||
| Stock Options [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Purchase of ordinary shares | 74,581 | 30,938 | ||||||||
| Grant options | $ / shares | $ 527,716 | |||||||||
| Grant approved | 704,669 | 785,775 | ||||||||
| Employees consideration | Employees | 22 | 27 | ||||||||
| Non-tradable options | 79,630 | 199,481 | ||||||||
| Consideration consultants | consultants | 2 | 2 | ||||||||
| Share based compensation, description | · 876,504 options were granted at an exercise prices of $1.97-$2.03 per share. 25% of the options vest and become exercisable on the first anniversary of the vesting commencement date. Thereafter, the options vest and become exercisable in 12 equal quarterly instalments of 6.25% each.· 108,752 options were granted at an exercise price of $1.69 per share and vest on variable vesting dates. | |||||||||
| Excercise price | $ / shares | $ 1.34 | $ 0.001 | ||||||||
| IPO [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Offering price | $ / shares | $ 10.00 | |||||||||
| Total gross proceeds | $ | $ 70,000 | |||||||||
| Consummated initial public offering | 7,000,000 | |||||||||
| Price Per Share | $ / shares | $ 11.50 | |||||||||
| Retained transaction | $ | $ 60,100 | |||||||||
| Private Placement [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Aggregate warrants shares | 2,900,000 | |||||||||
| Yeda [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Shares of issued warrants | 7,615 | |||||||||
| Founder [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Shares of issued warrants | 2,974 | |||||||||
| BiomX Isreal [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Exchange for common shares | 15,069,058 | |||||||||
| Shares outstanding, percentage | 65.00% | |||||||||
| Earnout shares, description | A. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share.B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share.C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share. | |||||||||
| Purchase of ordinary shares | 1 | |||||||||
| License Agreement [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Price Per Share | $ / shares | $ 0.0001 | |||||||||
| Warrants to purchase Ordinary Shares | 591,382 | |||||||||
| Series A Preferred Stock [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Preferred stock, shares issued | 3,028,990 | |||||||||
| Sale of stock, consideration | $ | $ 13,000 | |||||||||
| Series A Preferred Stock [Member] | Share Purchase Agreement [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Preferred stock, shares issued | 5,478,985 | |||||||||
| Preferred stock, par value | $ / shares | $ 0.0001 | |||||||||
| Sale of stock, consideration | $ | $ 30,155 | $ 31,955 | ||||||||
| Shares issued | 205,750 | |||||||||
| Series A Preferred Stock [Member] | Share Purchase Agreement [Member] | Investors [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Sale of stock, consideration | $ | $ 1,800 | $ 30,155 | ||||||||
| Shares issued | 308,628 | 4,964,607 | ||||||||
| Common Stock [Member] | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Common stock, shares issued | 60,000,000 | |||||||||
| Common stock, par value | $ / shares | $ 0.0001 | |||||||||
| Common stock, shares outstanding | 22,862,835 | |||||||||
| Preferred Stock | ||||||||||
| Shareholders Equity (Textual) | ||||||||||
| Preferred stock, shares issued | ||||||||||
| Preferred stock, par value | $ / shares | $ 0.0001 | |||||||||
| Preferred stock, shares authorized | 1,000,000 | |||||||||